Stock 575 REGENT PACIFIC GROUP LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Regent Pacific Group Limited Hong Kong S.E.

Equities

575

KYG3042R1231

Pharmaceuticals

End-of-day quote Hong Kong S.E.
Other stock markets
 23:00:00 04/02/2024 GMT 		5-day change 1st Jan Change
0.47 HKD -.--% Intraday chart for Regent Pacific Group Limited -17.54% -24.19%
07-02 Regent Pacific Group's Unit Terminates Disposal MT
07-02 Qujing Black Gold Energy Co., Ltd. cancelled the acquisition of 25% stake in West China Coking & Gas Company Limited from Regent Pacific Group Limited. CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 75.09 28.3 57.57 47.4 24.28 18.13
Enterprise Value (EV) 1 68.71 33.91 66.37 49.08 36.57 16.91
P/E ratio -2.42 x -0.43 x -1.83 x -3.73 x -0.67 x -0.71 x
Yield - - - - - -
Capitalization / Revenue 12 x 173 x 47.5 x 2.81 x 694 x 62.3 x
EV / Revenue 11 x 207 x 54.8 x 2.91 x 1,045 x 58.1 x
EV / EBITDA -27.9 x -3.55 x -10.9 x 5.7 x -6.3 x -2.95 x
EV / FCF 7.15 x 4.12 x 20.8 x 4.32 x 5.47 x 3.81 x
FCF Yield 14% 24.3% 4.82% 23.1% 18.3% 26.3%
Price to Book 0.59 x 0.45 x 1.14 x 1.22 x 9.35 x -11.7 x
Nbr of stocks (in thousands) 91,863 91,863 119,971 119,971 120,017 228,392
Reference price 2 0.8174 0.3081 0.4798 0.3951 0.2023 0.0794
Announcement Date 18/04/19 29/04/20 26/04/21 26/04/22 26/04/23 25/04/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 6.254 0.164 1.212 16.84 0.035 0.291
EBITDA 1 -2.461 -9.543 -6.097 8.607 -5.806 -5.735
EBIT 1 -30.56 -37.64 -25.53 -15.17 -30.77 -27.94
Operating Margin -488.65% -22,949.39% -2,106.6% -90.08% -87,925.71% -9,599.66%
Earnings before Tax (EBT) 1 -33.76 -64.73 -26.16 -15.09 -36.01 -30.46
Net income 1 -31.09 -66.05 -24.4 -12.6 -36.43 -25.05
Net margin -497.07% -40,273.17% -2,012.79% -74.79% -104,077.14% -8,607.9%
EPS 2 -0.3384 -0.7190 -0.2624 -0.1060 -0.3040 -0.1113
Free Cash Flow 1 9.611 8.225 3.198 11.35 6.684 4.445
FCF margin 153.68% 5,015.47% 263.88% 67.38% 19,097.5% 1,527.36%
FCF Conversion (EBITDA) - - - 131.87% - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 18/04/19 29/04/20 26/04/21 26/04/22 26/04/23 25/04/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - 5.61 8.8 1.68 12.3 -
Net Cash position 1 6.37 - - - - 1.22
Leverage (Debt/EBITDA) - -0.5877 x -1.443 x 0.1953 x -2.117 x -
Free Cash Flow 1 9.61 8.23 3.2 11.4 6.68 4.44
ROE (net income / shareholders' equity) -21.8% -69.8% -43.3% -28.3% -176% -4,789%
ROA (Net income/ Total Assets) -11.8% -20.4% -19.2% -13.3% -43.4% -120%
Assets 1 263.3 324.4 127.3 94.67 83.85 20.88
Book Value Per Share 2 1.380 0.6800 0.4200 0.3200 0.0200 -0.0100
Cash Flow per Share 2 0.0100 0 0.0200 0.0100 0 0.0100
Capex 1 0.07 0.01 0.01 0.04 0.01 0
Capex / Sales 1.09% 4.88% 0.58% 0.26% 34.29% 0.69%
Announcement Date 18/04/19 29/04/20 26/04/21 26/04/22 26/04/23 25/04/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+56.89% 823B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+39.52% 627B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.55% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.99% 320B
ABBVIE INC. Stock AbbVie Inc.
+7.92% 295B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.74% 239B
NOVARTIS AG Stock Novartis AG
+13.83% 220B
ROCHE HOLDING AG Stock Roche Holding AG
-0.49% 219B
AMGEN INC. Stock Amgen Inc.
+7.94% 167B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 575 Stock
  4. 575 Stock
  5. Financials Regent Pacific Group Limited